by Eric Christianson | Oct 31, 2021 | Medication and Disease State Clinical Pearls For Pharmacists
In clinical practice, I don’t see biologics in asthma very often, but it is something that I think is important to remember. The most commonly used agent over the years that I have seen is omalizumab (Xolair). According to the GINA guidelines, patients that have...
by Eric Christianson | Oct 27, 2021 | Long Term Care Consultant Pharmacist Education and Information
Working in long-term care, I’ve had the opportunity to audit medication carts and storage areas on a daily basis. In addition, surveyors will often cite deficiencies when they find expired medications. The most commonly cited medications that I’ve seen in...
by Eric Christianson | Oct 24, 2021 | Clinical Pharmacy News and New Drug Updates
FDA-approved biosimilars have been compared to a biologic and shown to be highly similar in structure and function. They are determined to have no clinically meaningful differences in safety, purity, or potency. At the time this article was written, there are...
by Eric Christianson | Oct 20, 2021 | Educational Case Studies For Pharmacists
CA is a 58-year-old female with CKD. Her CrCL today is 45 mL/min and stable sCr of 1.3 mg/dL. She complains of muscle aches that started a couple of weeks ago and that her doctor said she can’t use NSAIDs, even though the Tylenol doesn’t completely help the pain. She...
by Eric Christianson | Oct 17, 2021 | Medication and Disease State Clinical Pearls For Pharmacists
Statin myopathy is a primary reason why patients stop taking these cholesterol-lowering medications. Here’s a case scenario where I discuss considerations and options to addressing statin myopathy and adverse effect concerns from a patient. SE is a 58-year-old...
